Skip to main content
Journal cover image

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

Publication ,  Journal Article
Jahan, T; Gu, L; Kratzke, R; Dudek, A; Otterson, GA; Wang, X; Green, M; Vokes, EE; Kindler, HL
Published in: Lung Cancer
June 2012

INTRODUCTION: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant mesothelioma and to evaluate potential biomarkers of disease response (CALGB 30107). METHODS: Treatment consisted of vatalanib 1250 mg given orally once daily. CT scans were obtained at baseline and every 6 weeks thereafter. Baseline serum levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), thrombospondin-1 (TSP-1), and mesothelin were obtained. The primary endpoint was 3-month progression-free survival (PFS). RESULTS: Forty-seven patients enrolled at 19 centers. The median age was 75 years, and the majority of patients (79%) had an ECOG performance status of 1. Tumors were classified as epithelial (77%), sarcomatoid (10%), or mixed (9%) histology. Toxicity was mild; the most common grade 3/4 adverse events were neutropenia (2%), nausea (15%), elevated alanine aminotransferase (11%), hypertension (2%), and gastrointestinal bleeding (2%). Partial responses were observed in 6% of patients and stable disease in 72% of patients. The 3-month PFS rate was 55% (95% CI: 40%, 68%). The median PFS was 4.1 months. Median overall survival was 10.0 months. There was no correlation between serum levels of VEGF, PDGF, TSP-1, or mesothelin and treatment response, PFS, or survival. CONCLUSIONS: Vatalanib as a single agent with this dose and schedule does not warrant further study in this disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lung Cancer

DOI

EISSN

1872-8332

Publication Date

June 2012

Volume

76

Issue

3

Start / End Page

393 / 396

Location

Ireland

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Thrombospondin 1
  • Survival Analysis
  • Pyridines
  • Protein Kinase Inhibitors
  • Platelet-Derived Growth Factor
  • Phthalazines
  • Oncology & Carcinogenesis
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jahan, T., Gu, L., Kratzke, R., Dudek, A., Otterson, G. A., Wang, X., … Kindler, H. L. (2012). Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer, 76(3), 393–396. https://doi.org/10.1016/j.lungcan.2011.11.014
Jahan, Thierry, Lin Gu, Robert Kratzke, Arkadiusz Dudek, Gregory A. Otterson, Xiaofei Wang, Mark Green, Everett E. Vokes, and Hedy Lee Kindler. “Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).Lung Cancer 76, no. 3 (June 2012): 393–96. https://doi.org/10.1016/j.lungcan.2011.11.014.
Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, et al. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun;76(3):393–6.
Jahan, Thierry, et al. “Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).Lung Cancer, vol. 76, no. 3, June 2012, pp. 393–96. Pubmed, doi:10.1016/j.lungcan.2011.11.014.
Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun;76(3):393–396.
Journal cover image

Published In

Lung Cancer

DOI

EISSN

1872-8332

Publication Date

June 2012

Volume

76

Issue

3

Start / End Page

393 / 396

Location

Ireland

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Thrombospondin 1
  • Survival Analysis
  • Pyridines
  • Protein Kinase Inhibitors
  • Platelet-Derived Growth Factor
  • Phthalazines
  • Oncology & Carcinogenesis
  • Middle Aged